Claims for Patent: 9,221,882

Summary for Patent: 9,221,882

Title:	Biosynthetic proline/alanine random coil polypeptides and their uses
Abstract:	We discovered that a biosynthetic polypeptide, consisting of at least about 50 proline (Pro) and alanine (Ala) amino acid residues, forms a random coil, and increases the stability of other compounds to which it is conjugated, such as small molecules and polypeptides. We describe such biosynthetic polypeptides, constructs containing such polypeptides, ways of making them, and their use.
Inventor(s):	Skerra; Arne (Freising, DE), Binder; Uli (Freising, DE), Schlapschy; Martin (Freising, DE)
Assignee:	Technische Universitat Munchen (Munich, DE) XL-Protein GmbH (Freising, DE)
Application Number:	13/697,569
Patent Claims:	1. An isolated drug conjugate comprising (i) a random coil polypeptide comprising 50 to 3000 amino acids and consisting solely of proline and alanine, wherein said polypeptide forms a random coil, and (ii) a drug selected from (a) a biologically active polypeptide selected from the group consisting of antibodies, antibody fragments, Fab fragments, F(ab').sub.2 fragments, CDR-derived peptidomimetics, single chain variable fragments (scFv), domain antibodies, lectins, immunoglobulin domains, fibronectin domains, protein A domains, SH3 domains, ankyrin repeat domains, lipocalins, granulocyte colony stimulating factor, human growth hormone, alpha-interferon, beta-interferon, gamma-interferon, tumor necrosis factor, erythropoietin, coagulation factor VIII, gp120/gp160, soluble tumor necrosis factor I and II receptor, reteplase, exendin-4, anakinra, interleukin-2, neutrophil gelatinase-associated lipocalin, follicle-stimulating hormone, glucocerebrosidase, thymosin alpha 1, glucagon, somatostatin, adenosine deaminase, interleukin 11, coagulation factor VIIa, coagulation factor IX, hematide, lambda-interferon, leptin, interleukin-22 receptor subunit alpha (IL-22ra), interleukin-22, hyaluronidase, fibroblast growth factor 18, fibroblast growth factor 21, glucagon-like peptide 1, osteoprotegerin, IL-18 binding protein, growth hormone releasing factor, soluble TACI receptor, thrombospondin-1, soluble VEGF receptor Flt-1, and IL-4 mutein; and (b) a small molecule selected from the group consisting of digoxigenin, fluorescein, doxorubicin, calicheamicin, camptothecin, fumagillin, dexamethasone, geldanamycin, paclitaxel, docetaxel, irinotecan, cyclosporine, buprenorphine, naltrexone, naloxone, vindesine, vancomycin, risperidone, aripiprazole, palonosetron, granisetron, cytarabine, NX1838, leuprolide, goserelin, buserelin, octreotide, teduglutide, cilengitide, abarelix, enfuvirtide, ghrelin; wherein the drug is conjugated through a covalent link to the N- or C-terminus of the random coil polypeptide. 2. The drug conjugate of claim 1, wherein said random coil polypeptide consists of 10% to 75% proline residues. 3. The drug conjugate of claim 1, wherein said random coil polypeptide comprises a plurality of amino acid repeats wherein no more than 6 consecutive amino acid residues are the same amino acid. 4. The drug conjugate of claim 1, wherein said random coil polypeptide comprises an amino acid sequence selected from the group consisting of: TABLE-US-00009 (SEQ ID NO: 1) AAPAAPAPAAPAAPAPAAPA; (SEQ ID NO: 2) AAPAAAPAPAAPAAPAPAAP; (SEQ ID NO: 3) AAAPAAAPAAAPAAAPAAAP; (SEQ ID NO: 4) AAPAAPAAPAAPAAPAAPAAPAAP; (SEQ ID NO: 5) APAAAPAPAAAPAPAAAPAPAAAP; (SEQ ID NO: 6) AAAPAAPAAPPAAAAPAAPAAPPA; and (SEQ ID NO: 51) APAPAPAPAPAPAPAPAPAP; or circular permuted versions of any thereof. 5. The drug conjugate of claim 1, wherein the plasma half-life of the drug conjugate is longer than the drug lacking the random coil polypeptide. 6. A pharmaceutical composition comprising the drug conjugate of claim 1 and a pharmaceutically acceptable carrier. 7. A method for increasing the stability of a drug comprising conjugating the drug through a covalent link to the N- or C-terminus of a random coil polypeptide, wherein the drug is selected from (a) a biologically active polypeptide selected from the group consisting antibodies, antibody fragments, Fab fragments, F(ab').sub.2 fragments, CDR-derived peptidomimetics, single chain variable fragments (scFv), domain antibodies, lectins, immunoglobulin domains, fibronectin domains, protein A domains, SH3 domains, ankyrin repeat domains, lipocalins, granulocyte colony stimulating factor, human growth hormone, alpha-interferon, beta-interferon, gamma-interferon, tumor necrosis factor, erythropoietin, coagulation factor VIII, gp120/gp160, soluble tumor necrosis factor I and II receptor, reteplase, exendin-4, anakinra, interleukin-2, neutrophil gelatinase-associated lipocalin, follicle-stimulating hormone, glucocerebrosidase, thymosin alpha 1, glucagon, somatostatin, adenosine deaminase, interleukin 11, coagulation factor VIIa, coagulation factor IX, hematide, lambda-interferon, leptin, interleukin-22 receptor subunit alpha (IL-22ra), interleukin-22, hyaluronidase, fibroblast growth factor 18, fibroblast growth factor 21, glucagon-like peptide 1, osteoprotegerin, IL-18 binding protein, growth hormone releasing factor, soluble TACI receptor, thrombospondin-1, soluble VEGF receptor Flt-1, and IL-4 mutein and (b) a small molecule selected from the group consisting of digoxigenin, fluorescein, doxorubicin, calicheamicin, camptothecin, fumagillin, dexamethasone, geldanamycin, paclitaxel, docetaxel, irinotecan, cyclosporine, buprenorphine, naltrexone, naloxone, vindesine, vancomycin, risperidone, aripiprazole, palonosetron, granisetron, cytarabine, NX1838, leuprolide, goserelin, buserelin, octreotide, teduglutide, cilengitide, abarelix, enfuvirtide, and ghrelin; and the random coil polypeptide comprises 50 to 3000 amino acids and consists solely of proline and alanine, wherein said polypeptide forms a random coil. 8. The method for increasing the stability of a drug according to claim 7, wherein the drug is a biologically active polypeptide, comprising (a) cultivating in a culture medium a host cell comprising a nucleic acid encoding a drug conjugate comprising the biologically active polypeptide with the random coil polypeptide and (b) isolating the drug conjugate from the culture medium or from the cell. 9. The method of claim 8, wherein the drug conjugate is isolated from a cellular lysate, cellular membrane fraction, or periplasm of the host cell. 10. The method of claim 7, wherein the biologically active polypeptide is selected from the group consisting of antibodies, Fab fragments, F(ab').sub.2 fragments, single chain variable fragments (scFv), domain antibodies, lipocalins, granulocyte colony stimulating factor, human growth hormone, alpha-interferon, beta-interferon, coagulation factor VIII, exendin-4, anakinra, neutrophil gelatinase-associated lipocalin, follicle-stimulating hormone, glucocerebrosidase, coagulation factor VIIa, coagulation factor IX, leptin, fibroblast growth factor 21, glucagon-like peptide 1, and soluble VEGF receptor Flt 1. 11. The isolated drug conjugate of claim 1, wherein the drug is an antibody, Fab fragment, F(ab').sub.2 fragment, a single chain variable fragment (scFv), or a domain antibody. 12. The isolated drug conjugate of claim 1, wherein the drug is an Fab fragment. 13. The isolated drug conjugate of claim 1, wherein the drug is alpha-interferon. 14. The isolated drug conjugate of claim 1, wherein the drug is beta-interferon. 15. The isolated drug conjugate of claim 1, wherein the drug is leptin. 16. The isolated drug conjugate of claim 1, wherein the drug is glucagon-like peptide 1. 17. The isolated drug conjugate of claim 1, wherein the drug is exendin-4. 18. The isolated drug conjugate of claim 1, wherein the drug is human growth hormone. 19. The isolated drug conjugate of claim 1, wherein the drug is granulocyte colony stimulating factor. 20. The isolated drug conjugate of claim 1, wherein the drug is coagulation factor VIIa. 21. The isolated drug conjugate of claim 1, wherein the drug is coagulation factor VIII. 22. The isolated drug conjugate of claim 1, wherein the drug is coagulation factor IX. 23. The isolated drug conjugate of claim 1, wherein the drug is anakinra. 24. The isolated drug conjugate of claim 1, wherein the drug is follicle-stimulating hormone. 25. The isolated drug conjugate of claim 1, wherein the drug is glucocerebrosidase. 26. The isolated drug conjugate of claim 1, wherein the drug is fibroblast growth factor 21. 27. The isolated drug conjugate of claim 1, wherein the drug is soluble VEGF receptor Flt-1. 28. The isolated drug conjugate of claim 1, wherein the drug is a lipocalin. 29. The isolated drug conjugate of claim 1, wherein the drug is neutrophil gelatinase-associated lipocalin. 30. The isolated drug conjugate of claim 1, wherein the drug is enfuvirtide. 31. The isolated drug conjugate of claim 1, wherein the random coil polypeptide comprises an amino acid sequence of SEQ ID NO: 1 or a circular permuted version thereof. 32. The isolated drug conjugate of claim 1, wherein the random coil polypeptide comprises an amino acid of SEQ ID NO: 3 or a circular permuted version thereof. 33. The isolated drug conjugate of claim 1, wherein the drug is leptin and the random coil polypeptide comprises an amino acid sequence of SEQ ID NO: 1. 34. The isolated drug conjugate of claim 1, wherein the drug is anakinra and the random coil polypeptide comprises an amino acid sequence of SEQ ID NO: 1.

Details for Patent 9,221,882

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2030-05-21
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2030-05-21
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2030-05-21
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2030-05-21
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786	10/30/1996		2030-05-21
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	11/14/2001		2030-05-21